Dr. Gregory Mark Enns, MD

Dr. Enns practices at Lucile Packard Children's Hospital Stanford in Palo Alto, California, part of Stanford University.

Dr. Enns' NPI, 1508961897, was assigned on September 13, 2006. Dr. Enns graduated from University of Glasgow Faculty of Medicine in 1990. Dr. Enns holds California license A52095.

Dr. Enns' primary practice is Lucile Packard Children's Hospital Stanford, at 725 Welch Road, Palo Alto, CA 94304 in Santa Clara County. The practice phone is (650) 497-8000.

Dr. Enns' primary practice is Lucile Packard Children's Hospital Stanford in Palo Alto, California, part of Stanford University. The medical group on file is Lucile Packard Children's Hospital Stanford. Dmand AI also links Dr. Enns to 2 more medical groups, each named with a free account. Dr. Enns' employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Enns practices. Vendor and product names are available with a free account.

Medical biochemical genetics is Dr. Enns' primary specialty in the NPI Registry, under taxonomy code 207SG0207X. Dr. Enns is board certified in clinical biochemical genetics by the American Board of Medical Genetics and Genomics. Dmand AI has Dr. Enns' licenses on file in 4 states: California, Oregon, Hawaii and Florida.

CMS counts 13 Medicare patients who saw Dr. Enns in 2024. The largest group is 85 and over, with 0 patients. Their average risk score is 1.20, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Enns' median patient age at 13, with 55% women.

In 2016, Dr. Enns wrote 33 Medicare Part D claims. They cover 1 drug, with $2,827,732 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Enns for performance year 2024, reported as part of a group. Dr. Enns accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Enns as offering telehealth.

Dmand AI links 119 papers to Dr. Enns, published from 2005 to 2025. 2016 was the busiest year, with 8. The most frequent topics are Mitochondrial Diseases, Amino Acid Metabolism, Inborn Errors and Phenotype. Dr. Enns has published most often in Mol Genet Metab. Dr. Enns' most frequent co-authors are Fernando Scaglia, MD, Anna-Kaisa Niemi, MD, PhD and Bruce Howard Cohen, MD.

Dmand AI links Dr. Enns to 7 clinical trials, 4 of them phase 2 studies. 1 is still active or recruiting. Conditions studied include Leigh Disease, Methylmalonic acidemia and Carbamoyl-Phosphate Synthase I Deficiency Disease. Mendel Tuchman sponsors the most, 2.

CMS Open Payments shows 136 general payments to Dr. Enns from 14 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 73% of the total. Travere Therapeutics, Inc. paid the most, $36,039.

Dmand AI lists 2 awards for Dr. Enns, most recently Regional Top Doctor in 2014.

Dr. Enns graduated from University of Glasgow Faculty of Medicine in 1990. Dr. Enns is a member of AAP.

Dr. Enns is in network with 16 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Elevance. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.